AXSM - Axsome therapeutics initiates ACCORD phase 3 trial of AXS-05 in alzheimer's disease agitation

Axsome Therapeutics (AXSM) initiates ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) study, a Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AXS-05 in the treatment of Alzheimer’s disease agitation. AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. There is currently no approved treatment for AD agitation. “Initiation of the ACCORD Phase 3 trial in Alzheimer’s disease agitation continues the expedited clinical development of AXS-05 for this serious condition. The potential for AXS-05, with its unique pharmacological profile, in this indication is supported by the positive results in our completed pivotal ADVANCE trial,” said Herriot Tabuteau, MD, CEO.No treatments are currently approved for Alzheimer’s disease agitation.Source: Press Release

For further details see:

Axsome therapeutics initiates ACCORD phase 3 trial of AXS-05 in alzheimer’s disease agitation